Country: Jordan
Language: English
Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Palbociclib 75 mg
مستودع البتراء للمواد الطبية - Petra Drug Store
L01XE33
Palbociclib 75 mg
75 mg
21 Capsule
Pfizer Manufacturing Deutschland GmbH/Germany (المانيا)
PAA139441 HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE IBRANCE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR IBRANCE. IBRANCE ® (PALBOCICLIB) CAPSULES, FOR ORAL USE ------------------------------ RECENT MAJOR CHANGES ------------------------------ Dosage and Administration (2.2) 9/2019 Warnings and Precautions (5.2) 9/2019 ------------------------------ INDICATIONS AND USAGE ------------------------------- IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women • fulvestrant in women with disease progression following endocrine therapy. (1) --------------------------- DOSAGE AND ADMINISTRATION -------------------------- IBRANCE capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant. (2) • Recommended starting dose: 125 mg once daily taken with food for 21 days followed by 7 days off treatment. (2.1) • Dosing interruption and/or dose reductions are recommended based on individual safety and tolerability. (2.2) ------------------------ DOSAGE FORMS AND STRENGTHS -------------------------- Capsules: 125 mg, 100 mg, and 75 mg. (3) -------------------------------- CONTRAINDICATIONS ---------------------------------- None. (4) --------------------------- WARNINGS AND PRECAUTIONS --------------------------- • Neutropenia: Monitor complete blood count prior to start of IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated. (2.2, 5.1) • Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of ILD/ pneumonitis have been reported. Monitor for pulmonary symptoms of ILD/ pneumonitis. Interrupt IBRANCE immediately in patients with suspected ILD/ pneumonitis. Permanently Read the complete document